PIB TrackerIndia brings cell, gene and xenograft therapies under one national licensing net
The Centre amended the Drugs Rules, 1945 to place cell and stem-cell products, gene therapies and xenografts under the same joint Centre-State licensing regime as vaccines and blood products — ensuring uniform national regulation of these complex, fast-evolving advanced therapies.
What happened
- The central government amended the Drugs Rules, 1945 to bring three classes of advanced products — cell and stem-cell products, gene therapeutic products, and xenografts — under uniform national regulation.
- These categories are added to the joint Centre-State licensing regime operated through the Central Licence Approving Authority (CLAA), ensuring consistent oversight across states.
- The same tier already covers vaccines, large-volume parenterals (IV fluids) and recombinant-DNA-based medicines — categories judged critical enough for joint central and state supervision.
- Officials framed the move as a response to the complexity and rapid evolution of cell and gene therapies — such as CAR-T therapy for blood cancers, gene replacement/editing for genetic disorders, and xenograft heart valves.
- The amendment was notified in the official gazette; India's drug regulator, the CDSCO under the Drugs Controller General of India (DCGI), administers the framework.
For Prelims
- Drugs and Cosmetics Act, 1940 & Drugs Rules, 1945: The primary law and rules regulating the import, manufacture, distribution and sale of drugs and cosmetics in India for safety, quality and efficacy.
- CDSCO: The Central Drugs Standard Control Organisation (under the DGHS, Ministry of Health) — India's national drug regulator, headed by the Drugs Controller General of India (DCGI).
- CLAA: The Central Licence Approving Authority — the mechanism for joint central-and-state regulation of specified critical categories (e.g. vaccines, blood products, r-DNA medicines).
- Cell and gene therapies (CGT): Advanced treatments using living cells (e.g. stem cells) or genetic modification; CAR-T therapy re-engineers a patient's own immune cells to fight blood cancers.
- Xenograft: A tissue or organ transplanted from one species to another — e.g. animal-derived heart valves used in cardiac surgery.
- Recombinant DNA (r-DNA): Technology that combines DNA from different sources to produce biologics such as insulin and certain vaccines — already under the CLAA regime.
- Don't confuse: The CDSCO/DCGI is the central regulator; State Drug Control authorities license routine manufacture/sale — the CLAA framework makes regulation of these advanced products joint, not purely central.
For UPSC: Use this to show regulation keeping pace with frontier biotechnology — bringing cell, gene and xenograft therapies under uniform, joint Centre-State licensing so safety and quality are consistent nationwide. Link to the Drugs and Cosmetics Act 1940, CDSCO/DCGI, biotech policy, and India's emerging CGT ecosystem (e.g. the indigenous CAR-T therapy NexCAR19).
What it is NOT: This is a regulatory rule amendment defining who licenses these therapies and how, not a ban or a new approval of any specific product. It brings the products under joint central-state oversight; it does not, by itself, make any therapy available or affordable.
For Mains
Syllabus: GS3.13 · GS2.10 · Linkage L2
Anchor
Regulation catching up with frontier biotechnology — ensuring cell, gene and xenograft therapies are overseen uniformly and safely as India builds an advanced-therapies ecosystem.
Substantiation (data)
The Drugs Rules, 1945 amended to add cell/stem-cell products, gene therapeutics and xenografts to the joint Centre-State CLAA regime — the tier that already covers vaccines, IV fluids and r-DNA medicines.
Exemplification
Cite CAR-T therapy for blood cancers, gene editing for genetic disorders, and xenograft heart valves as concrete advanced therapies now under consistent national scrutiny.
Problematisation
Challenges include very high therapy costs and access, ethical questions in gene editing and xenotransplantation, capacity of regulators to assess novel science, and post-market safety monitoring.
Way-forward
Build regulatory and evaluation capacity, clear ethics and pharmacovigilance frameworks, support affordable indigenous CGT (like NexCAR19), and harmonise central-state licensing in practice.
Position
Government stance: uniform, joint regulation ensures safety, quality and public trust in advanced therapies while enabling India's biotech and healthcare innovation.
Deploys into: Biotechnology and its regulation (GS3.13 IT, space, bio & IPR) · government policy and regulatory frameworks for health (GS2.10 government policies & interventions) · advanced therapies, CDSCO/DCGI and health-sector innovation.
Ministry of Health and Family Welfare · 2026-07-02 · PRID 2280408 · PIB source ↗